LL-37 Guide (2026)
Complete Guide & Evidence (2026)
Human cathelicidin antimicrobial peptide — part of the innate immune system. Antiviral, antibiofilm, wound healing.
How LL-37 Works
Antimicrobial Action
Disrupts bacterial cell membranes directly. Kills gram-positive and gram-negative bacteria. Active against drug-resistant strains (MRSA)
Biofilm Disruption
Penetrates and dismantles bacterial biofilms. Enhances antibiotic penetration. Key for chronic Lyme and SIBO protocols
Immune Modulation
Activates innate immune cells. Antiviral: inhibits influenza, HIV, SARS-CoV-2. Promotes wound healing and angiogenesis
Key Research Data
Daily subcutaneous dose used in most reported research protocols.
Reduction in P. aeruginosa biofilm biomass at physiologic LL-37 concentrations.
Active against influenza A/B, RSV, HIV, HSV, and multiple other viral families.
LL-37 Protocol Overview
Timing: Morning administration is typically preferred due to immune activation. Many practitioners stack LL-37 with BPC-157 or thymosin alpha-1 for synergistic immune modulation.
Side Effects & Considerations
Common Side Effects
Immune activation response (flu-like, 1–3 days). Injection site redness or warmth. Herxheimer-like reaction with pathogen die-off
Cautions
Avoid in active autoimmune flares without guidance. High doses may overstimulate immune system. Monitor inflammatory markers during long cycles
Vital Protocol FAQs
What is LL-37 peptide?
LL-37 is the only member of the cathelicidin family of antimicrobial peptides expressed in humans. It is part of the innate immune system, secreted by neutrophils, epithelial cells, and macrophages in
What dose of LL-37 is used in research protocols?
Research protocols most commonly report 50–100 mcg/day subcutaneously, typically taken in the morning due to its immune-activating properties. Some aggressive immune-support protocols use up to 200 mc
Who uses LL-37 peptide?
LL-37 is primarily used by people dealing with chronic infections, biotoxin illness (mold/Lyme), recurrent respiratory infections, and biofilm-related conditions. Some researchers are investigating it
What are the side effects of LL-37?
The most commonly reported side effect is a strong immune activation response — fatigue, flu-like feelings, or warmth in the first 1–3 days as the immune system upregulates. Injection site reactions a
Guide FAQs
Human cathelicidin antimicrobial peptide — part of the innate immune system. Antiviral, antibiofilm, wound healing.
Yes. Shotlee supports tracking LL-37 doses, side effects, and health metrics. It is free to use.
References
Track Your LL-37 Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.
🚀 Use Shotlee for Free